Search for: "In Re: Risperdal Litig."
Results 1 - 20
of 31
Sort by Relevance
|
Sort by Date
20 Nov 2019, 10:25 am
(In re Risperdal Litig.). [read post]
2 Mar 2018, 11:26 am
They’re pretty standard fare on mid-afternoon and late-night television. [read post]
29 Aug 2016, 1:19 pm
While patients have several complaints about the drug, the current multi-district litigation (MDL) directed at Johnson & Johnson focuses mainly on one very uncomfortable side effect of Risperdal and/or Invega use. [read post]
22 Jul 2016, 9:03 am
Conserve Hip Implant Products Liability Litigation (MDL No. 2329); Christiansen, No. 13-00297 (N.D. [read post]
6 May 2016, 8:00 am
” In re Vioxx Products Liability Litigation, 230 F.R.D. 473 (E.D.Aa. 2005). [read post]
28 Oct 2015, 4:30 am
In Re Risperdal Litigation, 2015 Phila. [read post]
31 Aug 2014, 9:18 am
Ontario construction law boutique Robson Carpenter is looking for a litigation lawyer to join their team. [read post]
21 Mar 2014, 11:38 am
We do this blog not just to tout good results, slam bad decisions, and relay our likes and dislikes on various subjects, but to provide information that can help drug and device manufacturer defendants get better results in the litigations they face. [read post]
19 Nov 2013, 6:54 pm
The master case is In re Topamax Litigation, 110602131, Court of Common Pleas, Philadelphia County, Pennsylvania. [read post]
19 Nov 2013, 6:49 pm
The consolidated federal case is In re DePuy Orthopedics Inc., ASR Hip Implant Products Liability Litigation, 10-MD-2197, U.S. [read post]
4 Nov 2013, 9:56 pm
” When Janssen received the initial results of studies indicating that Risperdal posed the same diabetes risk as other antipsychotics, the complaint alleges that the company retained outside consultants to re-analyze the study results and ultimately published articles stating that Risperdal was actually associated with a lower risk of developing diabetes.The complaint alleges that, despite the FDA warnings and increased health risks, from 1999 through 2005, Janssen… [read post]
9 Aug 2012, 5:00 am
Pfizer (femoral stem) Deposition1998-09-18 In re AMS Minnesota Penile Prosthesis Litigation Deposition1998-11-25 Mason v. [read post]
16 Apr 2012, 1:37 pm
As long as the company warned about the risks of the drugs, they’re essentially immune from liability, even if the drugs weren’t properly tested, even if they were deceptively marketed, and even if the drug didn’t perform as promised. [read post]
2 Mar 2012, 6:52 am
Pfizer (femoral stem) Deposition1998-09-18 In re AMS Minnesota Penile Prosthesis Litigation Deposition1998-12-22 Ethicon, Inc. v. [read post]
30 May 2011, 10:16 pm
Reforms billed as loser-pays advance in Texas, but they’re very scaled-down [WSJ, WLF and more, Legal Blog Watch, Wood/PoL, Cary Gray/Houston Chronicle, WSJ Law Blog, earlier] “Refutation of Toyota sudden acceleration hysteria doesn’t stop Toyota sudden acceleration litigation” [Ted at PoL] “Five Questions With Legal Scholar Richard Epstein” [Jamie Weinstein, Daily Caller; his views on Title IX] Employers glad for small favors: “Refusing… [read post]
30 Nov 2010, 6:02 am
Plus, because the letters aren’t final agency action, they’re not subject to judicial review for want of ripeness. [read post]
28 Jun 2010, 3:50 am
The Commonwealth relied on In re Zyprexa Products Liability Litigation, 671 F Supp 2d 397 (EDNY 2009). [read post]
21 Sep 2009, 4:03 am
In the underlying case, the Commonwealth seeks damages for asserted financial harm allegedly caused by Janssen’s supposed deceptive marketing practices in promoting its anti-psychotic drug, Risperdal, for off-label uses. [read post]
13 Aug 2009, 4:07 am
The litigation was directly contrary to the actions of the Commonwealth's own plan administrators, who continue to list Risperdal as a "preferred" drug. [read post]
31 Oct 2008, 11:53 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Oxytrol (Oxybutynin) - US: Watson files patent infringement lawsuit against Barr over application to market generic Oxytrol; Barr challenges Oxytrol patent… [read post]
